Konstantin Tachkov
Konstantin Tachkov
Medical University of Sofia - Faculty of Pharmacy
Потвърден имейл адрес: pharmfac.mu-sofia.bg
Fixed dose drug combinations–are they pharmacoeconomically sound? Findings and implications especially for lower-and middle-income countries
B Godman, H McCabe, T D Leong, D Mueller, AP Martin, I Hoxha, ...
Expert review of pharmacoeconomics & outcomes research 20 (1), 1-26, 2020
Antimicrobial activity, mechanism of action, and methods for stabilisation of defensins as new therapeutic agents
M Amerikova, I Pencheva El-Tibi, V Maslarska, S Bozhanov, K Tachkov
Biotechnology & Biotechnological Equipment 33 (1), 671-682, 2019
The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
E Moorkens, B Godman, I Huys, I Hoxha, A Malaj, S Keuerleber, ...
Frontiers in pharmacology 11, 591134, 2021
Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income …
B Godman, C Grobler, M Van-De-Lisle, J Wale, WB Barbosa, A Massele, ...
Expert opinion on pharmacotherapy 20 (18), 2237-2255, 2019
Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria
K Tachkov, K Mitov, Y Koleva, Z Mitkova, M Kamusheva, M Dimitrova, ...
PloS one 15 (5), e0232815, 2020
Cost-of-illness studies in nine Central and Eastern European countries
V Brodszky, Z Beretzky, P Baji, F Rencz, M Péntek, A Rotar, K Tachkov, ...
The European Journal of Health Economics 20, 155-172, 2019
The current situation regarding long-acting insulin analogues including biosimilars among African, Asian, European, and South American countries; findings and implications for …
B Godman, M Haque, T Leong, E Allocati, S Kumar, S Islam, J Charan, ...
Frontiers in public health 9, 671961, 2021
Quality of life and cost study of rheumatoid arthritis therapy with biological medicines
VV Boyadzieva, N Stoilov, RM Stoilov, K Tachkov, M Kamusheva, K Mitov, ...
Frontiers in pharmacology 9, 794, 2018
Evaluation of the economic and social burden of chronic obstructive pulmonary disease (COPD)
K Tachkov, M Kamusheva, V Pencheva, K Mitov
Biotechnology & Biotechnological Equipment 31 (4), 855-861, 2017
New epidemiological, clinical and economic data for patients with acromegaly in Bulgaria
M Kamusheva, S Vandeva, K Mitov, Y Rusenova, A Elenkova, ...
Frontiers in Public Health 8, 147, 2020
Impact of polypharmacy, drug-related problems, and potentially inappropriate medications in geriatric patients and its implications for Bulgaria—narrative review and meta-analysis
T Krustev, P Milushewa, K Tachkov
Frontiers in Public Health 10, 743138, 2022
A systematic review of collective evidences investigating the effect of diabetes monitoring systems and their application in health care
M Kamusheva, K Tachkov, M Dimitrova, Z Mitkova, G García-Sáez, ...
Frontiers in endocrinology 12, 636959, 2021
Barriers to use artificial intelligence methodologies in health technology assessment in central and east European countries
K Tachkov, A Zemplenyi, M Kamusheva, M Dimitrova, P Siirtola, J Pontén, ...
Frontiers in Public Health 10, 921226, 2022
Orphan medicinal products’ access to the Bulgarian pharmaceutical market–challenges and obstacles
M Kamusheva, K Tachkov, G Petrova, A Savova, M Manova
Expert Opinion on Orphan Drugs 6 (2), 95-104, 2018
Prevalence of potentially inappropriate prescribing in older adults in Central and Eastern Europe: a systematic review and synthesis without meta-analysis
J Brkic, D Fialova, B Okuyan, I Kummer, S Sesto, A Capiau, ...
Scientific reports 12 (1), 16774, 2022
Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes
K Urbańczyk, S Guntschnig, V Antoniadis, S Falamic, T Kovacevic, ...
Frontiers in pharmacology 14, 1244151, 2023
Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria
M Vassileva, M Kamusheva, M Manova, A Savova, K Tachkov, G Petrova
Expert review of pharmacoeconomics & outcomes research 19 (6), 733-742, 2019
Chronic obstructive pulmonary disease exacerbations and progression in relation to ambient air pollutants exposure
M Doneva, G Petrova, D Petrova, M Kamusheva, V Petkova, K Tachkov, ...
Journal of Thoracic Disease 11 (6), 2490, 2019
Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting
M Dimitrova, G Petrova, K Tachkov, MK Bozhkova, M Kamusheva, K Mitov
Biotechnology & Biotechnological Equipment 28 (2), 366-371, 2014
Using real-world evidence in healthcare from Western to Central and Eastern Europe: a review of existing barriers
M Kamusheva, B Németh, A Zemplényi, Z Kaló, J Elvidge, M Dimitrova, ...
Journal of Comparative Effectiveness Research 11 (12), 905-913, 2022
Системата не може да изпълни операцията сега. Опитайте отново по-късно.
Статии 1–20